Eli Lilly (NYSE:LLY) has entered into a licensing agreement with Mediar Therapeutics to advance Mediar's drug MTX-463 into ...

Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

Scotland has the highest rate of drugs deaths in Europe, with fatalities rising by 12 in a year to 1,172 drug-related deaths in 2023.

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...

The U.S. FDA has provided advice for Tiakis Biotech's Phase 2 clinical trial of tiprelestat for pulmonary arterial ...

A Winnipeg woman who trained as a doctor in the Philippines says she doesn't trust the Manitoba health care system after ...

Viatris' generic of Symbicort (budesonide and formoterol fumarate dihydrate) – developed by Viatris in collaboration with 3M spin-off company Kindeva Drug Delivery and called Breyna – has been ...

The integration of artificial intelligence (AI) into healthcare has opened new frontiers for improving patient care and ...

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company's Response to a Wells Notice from ...

Norm has received breakthrough device designation from the Food and Drug Administration, giving Fire1 additional access to the agency as it works to bring the product to market. The early feasibility ...